Dr. Wierda on the Need for Continuous Treatment for CLL

William G. Wierda, MD, PhD
Published: Thursday, May 04, 2017



William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discusses the need for continuous treatments for patients with chronic lymphocytic leukemia (CLL).

One challenge is the need for continuous treatment, states Wierda. If patients recieve a small molecule inhibitor, they have high disease control but they still have measurable disease. If the patient no longer receives the medicine, the disease will continue to grow.

Currently, researchers are aiming to develop non-chemotherapy regimens, either by sequencing the drugs or combinations that will allow for a treatment-free period.
 


William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discusses the need for continuous treatments for patients with chronic lymphocytic leukemia (CLL).

One challenge is the need for continuous treatment, states Wierda. If patients recieve a small molecule inhibitor, they have high disease control but they still have measurable disease. If the patient no longer receives the medicine, the disease will continue to grow.

Currently, researchers are aiming to develop non-chemotherapy regimens, either by sequencing the drugs or combinations that will allow for a treatment-free period.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x